Compare Summit Therapeutics Inc (SMMT) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Warner Music Group Corp — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Warner Music Group Corp trades at $28.16 (market cap $14.73B). The key difference: Summit Therapeutics Inc and Warner Music Group Corp are close in size by market cap, and Warner Music Group Corp pays a 2.84% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WMG | |
|---|---|---|
Market Cap | $13.98B | $14.73B |
Sector | Health | Media |
52-Week High | $26.38 | $34.72 |
52-Week Low | $12.43 | $23.65 |
Enterprise Value | $13.31B | $19.03B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent quarterly earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, and recent news highlights AI partnerships and licensing renewals.
Outlook is positive due to strong streaming growth and strategic AI initiatives, but risks include margin pressure and leadership changes. The stock offers value with a P/E of 22.42 and robust cash flow, though near-term volatility may persist amid market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
